Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 211 entries
View as:

Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06849167 Org: User:
Start: 03/01/25 End: 03/01/30 Due: 03/01/31

A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST

Phase: N/A Priority: Normal
NCT ID: NCT02776878 Org: User:
Start: 05/31/16 End: 05/31/18 Due: 05/31/19

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05985707 Org: User:
Start: 08/15/23 End: 12/31/26 Due: 12/31/27

Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05529615 Org: User:
Start: 11/01/22 End: 05/01/29 Due: 05/01/30

Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04206358 Org: User:
Start: 05/13/19 End: 12/31/23 Due: 12/31/24

68Ga-ICAM-1pep PET/CT in Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04596670 Org: User:
Start: 09/20/24 End: 12/31/25 Due: 12/31/26

Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe

Phase: N/A Priority: Normal
NCT ID: NCT06203119 Org: User:
Start: 10/01/22 End: 10/31/24 Due: 10/31/25

Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06757387 Org: User:
Start: 12/30/24 End: 12/30/30 Due: 12/30/31

Endoscopic Ultrasound in Detailed T-staging of Upper GI Malignancies in Vitro

Phase: N/A Priority: Normal
NCT ID: NCT02226224 Org: User:
Start: 06/30/14 End: 10/31/20 Due: 10/31/21

Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06690541 Org: User:
Start: 11/10/24 End: 10/31/30 Due: 10/31/31

Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging

Phase: N/A Priority: Normal
NCT ID: NCT06715020 Org: User:
Start: 12/31/24 End: 12/31/26 Due: 12/31/27

Registry Study in MSI/dMMR Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06004713 Org: User:
Start: 10/07/23 End: 02/28/26 Due: 02/28/27

PD-L1 Targeting Molecular Imaging of Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04629326 Org: User:
Start: 07/20/21 End: 11/30/24 Due: 11/30/25

Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients

Phase: N/A Priority: Normal
NCT ID: NCT04422457 Org: User:
Start: 06/13/20 End: 03/01/22 Due: 03/01/23

Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT06894797 Org: User:
Start: 04/01/25 End: 10/31/27 Due: 10/31/28

Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02860234 Org: User:
Start: 08/31/16 End: 11/30/19 Due: 11/30/20

18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03051581 Org: User:
Start: 03/01/17 End: 12/31/20 Due: 12/31/21

RSYR for Fatigue Reduction in Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT03911921 Org: User:
Start: 06/01/15 End: 02/01/19 Due: 02/01/20

Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT05104801 Org: User:
Start: 11/30/21 End: 09/30/23 Due: 09/30/24

Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07004712 Org: User:
Start: 06/01/25 End: 09/01/28 Due: 09/01/29

Research for the Molecular Imaging of the PD-L1 Targeting Tracer

Phase: N/A Priority: Normal
NCT ID: NCT04304066 Org: User:
Start: 08/06/19 End: 12/31/24 Due: 12/31/25

Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04479527 Org: User:
Start: 04/30/21 End: 12/31/23 Due: 12/31/24

CLDN18.2 Targeting PET Imaging in Patients With Gastrointestinal Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04883970 Org: User:
Start: 05/13/21 End: 05/31/24 Due: 05/31/25

A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

Phase: N/A Priority: Normal
NCT ID: NCT06549907 Org: User:
Start: 01/10/24 End: 09/30/28 Due: 09/30/29

Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03286920 Org: User:
Start: 09/20/17 End: 09/30/18 Due: 09/30/19